Rexahn Pharmaceuticals, Inc. (REXN)

[Theo]

"Investing in early biotechnology companies carries many risks, the first and foremost being failure of clinical trials. Another risk of holding long-term is dilution...the best prices on company stock are often obtained deep into expensive pivotal phase 3 clinical trials after successive dilution..."

I like RNN's potential and was in an out of it last year. The announced R/S killed any short-term interest I might have had. I did (and continue) to keep it on "watch". I will not not, however, even consider buying a position now until after the R/S and the subsequent fade following. Best to let this one go do its thing for a few months monitoring possible Insider activity as well as any conferences they might be speaking at for glimpses or a "feel" into how the phase II trials are progressing for a chance at a flip until they can get some solid footing imo.